Sanara MedTech Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Für Sanara MedTech wird ein Gewinn- und Umsatzwachstum von 105.5% bzw. 11.7% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 102.8% pro Jahr steigen soll.
Wichtige Informationen
105.5%
Wachstumsrate der Gewinne
102.76%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.1% |
| Wachstumsrate der Einnahmen | 11.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 12 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 21
SMTI: Cost Effectiveness Evidence Will Support Future Upside Under Bullish Initiation
Analysts have maintained their $34.00 price target on Sanara MedTech, pointing to slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that align with a recently initiated bullish view on the stock. Analyst Commentary Bullish Takeaways Bullish analysts point to the maintained US$34.00 target as consistent with their constructive view, seeing current assumptions on discount rate, revenue growth, profit margin and future P/E as reasonable within their framework.Narrativ-Update • May 03
SMTI: Bullish Initiation And Cost Effectiveness Evidence Will Support Future Upside
Analysts have reaffirmed a $34.00 price target for Sanara MedTech, citing a fresh bullish initiation that highlights the company’s long term growth potential and supports unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed US$34.00 target as supported by the current fair value framework, with assumptions on discount rate, revenue growth, profit margin, and future P/E kept intact.Narrativ-Update • Apr 19
SMTI: Bullish Coverage And Cost Effectiveness Study Will Support Future Upside
Analysts have reduced their price target on Sanara MedTech by $2 to $34. This reflects updated views on growth, profitability, and a higher assumed future P/E, following recent bullish Street initiation commentary.Narrativ-Update • Mar 21
SMTI: Surgical Economics And Higher Margins Will Support Future Upside
Analysts have lowered their price target for Sanara MedTech from $40 to $36, citing revised fair value estimates, along with updated assumptions for revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News A peer-reviewed study in the Journal of Medical Economics evaluates CellerateRX Surgical Powder as an add-on to standard care in high risk spinal surgery.Narrativ-Update • Mar 05
SMTI: New Revenue Guidance And Surgical Pipeline Will Support Future Upside
Analysts have kept Sanara MedTech's fair value estimate steady at $40.00 per share, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs that reflect fine tuning rather than a change in overall conviction. What's in the News Sanara MedTech issued new guidance for the fourth quarter of 2025, with expected net revenue between $27.2 million and $27.7 million.Narrativ-Update • Feb 19
SMTI: Surgical Portfolio And Guidance Will Support Future Upside Potential
Analysts have maintained their $40.00 price target for Sanara MedTech, citing only very small adjustments to assumptions such as discount rate, long term revenue growth, profit margin and future P/E that did not materially change their overall valuation view. What's in the News Issued revenue guidance for Q4 2025, with expected net revenue in a range of $27.2 million to $27.7 million and commentary on the impact of approximately $1.8 million of BIASURGE sales in Q4 2024 on year over year comparisons (Corporate Guidance).Narrativ-Update • Feb 04
SMTI: Core Surgical Focus Will Drive Future Upside Potential
Analysts have modestly adjusted their price target for Sanara MedTech to US$40.00. This reflects small updates to assumptions around discount rate, revenue growth, profit margin and future P/E that keep their overall valuation view essentially unchanged.Narrativ-Update • Jan 21
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have trimmed their price target on Sanara MedTech from US$41 to US$40, reflecting updated assumptions around profit margins and future P/E expectations while keeping the overall long term growth story intact. What's in the News BIASURGE Advanced Surgical Solution received an Innovative Technology contract from Vizient Inc., signaling unique product qualities recognized by hospital experts on Vizient's client led councils (Key Developments).Narrativ-Update • Jan 07
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Sanara MedTech steady at US$41.00. This reflects only small tweaks to their underlying assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock.Narrativ-Update • Dec 14
SMTI: Core Surgical Focus Will Drive Future Profit Expansion And Upside Potential
Analysts have raised their price target for Sanara MedTech to approximately $41.00 per share, reflecting slightly lower discount rate assumptions and a marginally improved outlook for the company’s long term valuation multiples. What's in the News Sanara MedTech and Biomimetic Innovations provided an update on their strategic alliance focused on advancing orthopedic solutions and commercial readiness for new products (Key Developments).Narrativ-Update • Nov 29
SMTI: Leadership Transition And Discontinued Operations Will Drive Profit Expansion Ahead
Analysts have reiterated their previous price target for Sanara MedTech at $41.00. They cite minimal changes in key financial assumptions and maintain a stable outlook for the company.Narrativ-Update • Nov 15
SMTI: Leadership Transition And Streamlined Operations Will Drive Profitability Expansion
Narrative Update on Sanara MedTech: Analyst Price Target Revision Analysts have lowered their price target for Sanara MedTech from $50.00 to $41.00, citing updated estimates for key valuation metrics and a moderation in projected revenue growth. What's in the News Sanara MedTech is discontinuing operations of Tissue Health Plus (THP) to improve operating efficiency and will reclassify THP as discontinued operations in financial statements.Analyseartikel • Aug 13
Sanara MedTech Inc. (NASDAQ:SMTI) Doing What It Can To Lift Shares
With a median price-to-sales (or "P/S") ratio of close to 2.7x in the Medical Equipment industry in the United States...
Neues Narrativ • Mar 31
Tissue Health Plus And OsStic Will Expand Market Reach
Expansion in sales coverage and partnerships aims to boost product adoption, enhancing revenue in both new and existing markets.Seeking Alpha • Jan 30
Sanara MedTech: A Promising Growth Story At An Attractive Valuation
Summary Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic opportunities. While the surgical segment is solidly profitable, overall profitability is depressed by losses in Sanara’s pre-commercialization segment. At 3 times revenue, I find the current valuation attractive, and hence I am assigning shares a Buy rating. Read the full article on Seeking AlphaAnalyseartikel • Dec 19
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 15
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) defied analyst predictions to release its quarterly results, which were ahead of...Analyseartikel • Sep 05
Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump
Sanara MedTech Inc. ( NASDAQ:SMTI ) shares have had a really impressive month, gaining 28% after a shaky period...Analyseartikel • Aug 14
Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • May 23
Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story
There wouldn't be many who think Sanara MedTech Inc.'s ( NASDAQ:SMTI ) price-to-sales (or "P/S") ratio of 3.8x is worth...Analyseartikel • Nov 15
Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • May 22
Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)
You may think that with a price-to-sales (or "P/S") ratio of 5.8x Sanara MedTech Inc. ( NASDAQ:SMTI ) is a stock to...Analyseartikel • Mar 22
Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) last week reported its latest annual results, which makes it a good time for...Seeking Alpha • Sep 06
Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure
Summary Sanara MedTech has caught a bid since the June roll and looks attractively priced at its current market cap. Q2 earnings were strong and demonstrated the company is capturing market share. We see shares offer a 25% pricing asymmetry to the upside based on forward-looking sales multiples. We rate SMTI a buy. Investment summary We continue to see selective opportunities within US medical devices as investors look to shift up the quality spectrum. One such name is Sanara MedTech Inc. (SMTI), a differentiated offering with niche exposure to wound care. The primary value proposition lies within the Cellerate portfolio, however, there looks to be a gap in current fundamentals to forward expectations. This has created a pricing asymmetry to the upside where we see shares fairly valued at $39. Rate buy on these factors. Q2 earnings comments The company derives the bulk of revenue volume from sales of the CellerateRX surgical powder. This is a hydrolyzed collagen that is indicated for surgical and non-surgical wound care, burns included. Collagen actually plays an important role in tissue healing throughout all stages of repair. There are numerous studies corroborating its efficacy in these applications. Globally, the hydrolyzed collagen market was recently valued at US$1.09 billion and was forecast to climb at a CAGR of 7.8% by 2032 to a market value of US$2.34 billion. CellerateRX is a long-term compounder with exciting economics tied into the mix by our estimation. By the end of Q2, it was being sold in ~590 hospitals and ambulatory centres in 27 states. It is approved to be sold in a total of 1,580 facilities. Management estimates the total addressable market for CellerateRX, measured in terms of hospitals and ambulatory centres, is ~12,000 facilities in the US. Net quarterly revenues of $9.7 million ("mm") grew 54% YoY and was comprised primarily of organic growth. For the six months to date, revenue was $17.5mm, meaning the bolus of revenue was generated in Q2. The increase in sales was underscored by continued adoption of the Cellerate portfolio throughout the quarter. The gain of 54% is well above market growth trends and suggests to us that SMTI captured additional market share during the quarter. The Scendia Biologics acquisition was also completed and this adds an entire suite of complementary biologics products and tuck-ins to the Cellerate portfolio. In particular, the acquisition looks accretive to the company's cellular and bone matrix offerings, Amplify and Allocyte. These are differentiated offerings in a complex segment of osteo-cartilaginous tissue repair, where treatment failure rates are high. Scendia clipped revenue of $8.3mm in FY21. SMTI's goal is to expand Scendia into an additional 18 states and eventually reach all 50 states. We estimate the deal to show accretion to the bottom line as early as the next quarter. Reconciliations to GAAP earnings Considering where SMTI allocated capital during the past 12 months and last quarter, several adjustments to GAAP earnings must be made in order to understand how much the company invested, where it allocated capital and the return on this investment. As seen in Exhibit 1, we have capitalized 100% if the R&D investment and reconciled $412,000 in non-cash spend that was expensed on the income statement. This results in an improved operating loss and net loss to $1.06mm and $1.12mm respectively. In consequence, we estimate non-GAAP quarterly earnings to be at a negative $0.14 per share for the company. These adjustments also see a shift in shareholder equity up from $35.45mm to $35.86mm. Exhibit 1. Reconciled earnings from GAAP accounting reveal narrower net-loss and improved EPS. Data: SMTI 10-Q Q2 FY22 Factors to consider for valuation Measures of value are where the risk/reward calculus begins to turn bullish for STMI in our estimation. As seen below in Exhibit 2, these are high quality assets we are buying into, with liabilities made up of accruals and operating leases. The absence of a goodwill ledger on the balance sheet presents a clean asset value. Pleasingly, inventory value only saw a marginal increase YoY whilst inventory turnover was flat at 2x. Following acquisitions made throughout the year, the company booked growth of 359% YoY in intangible asset value, lifting total assets and book value by more than $10mm. As seen in Exhibit 3, clarity is provided on the fair value of these investments. We are satisfied there is validity in the fair value of these investments, and note the $1.6mm amortization schedule on a straight line basis. Exhibit 2. Note the absence of goodwill, despite recent acquisitions and increase to intangible asset value. This is a 'clean' balance sheet that can continue to be put to effective use, by estimation. Data: SMTI 10-Q Q2 FY22 Exhibit 3. SMTI intangibles are well-defined, and validate their presence on the balance sheet. This is essential as oftentimes intangibles are booked precariously and do not warrant inclusion in measures of corporate value.Seeking Alpha • Aug 15
Sanara MedTech reports Q2 results
Sanara MedTech press release (NASDAQ:SMTI): Q2Revenue of $9.7M (+54.5% Y/Y) beats by $1M. Net loss of $3.3 millionGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2027 | 132 | 5 | N/A | N/A | 1 |
| 12/31/2026 | 118 | 2 | N/A | N/A | 2 |
| 3/31/2026 | 107 | 1 | 3 | 6 | N/A |
| 12/31/2025 | 103 | 0 | 2 | 7 | N/A |
| 9/30/2025 | 102 | -1 | -1 | 4 | N/A |
| 6/30/2025 | 97 | 1 | 0 | 4 | N/A |
| 3/31/2025 | 92 | -1 | -2 | 0 | N/A |
| 12/31/2024 | 87 | -2 | 0 | 0 | N/A |
| 9/30/2024 | 78 | -3 | -2 | -2 | N/A |
| 6/30/2024 | 72 | -7 | -3 | -3 | N/A |
| 3/31/2024 | 68 | -5 | -3 | -3 | N/A |
| 12/31/2023 | 65 | -4 | -4 | -3 | N/A |
| 9/30/2023 | 63 | -8 | -3 | -3 | N/A |
| 6/30/2023 | 60 | -9 | -4 | -6 | N/A |
| 3/31/2023 | 54 | -6 | -6 | -5 | N/A |
| 12/31/2022 | 46 | -8 | -6 | -6 | N/A |
| 9/30/2022 | 38 | -7 | -8 | -7 | N/A |
| 6/30/2022 | 30 | -8 | -9 | -6 | N/A |
| 3/31/2022 | 27 | -10 | -6 | -6 | N/A |
| 12/31/2021 | 24 | -8 | -6 | -5 | N/A |
| 9/30/2021 | 22 | -5 | -5 | -4 | N/A |
| 6/30/2021 | 20 | -4 | -3 | -3 | N/A |
| 3/31/2021 | 17 | -4 | -4 | -3 | N/A |
| 12/31/2020 | 16 | -4 | -6 | -4 | N/A |
| 9/30/2020 | 14 | -6 | -6 | -4 | N/A |
| 6/30/2020 | 13 | -5 | -6 | -4 | N/A |
| 3/31/2020 | 13 | -4 | -6 | -4 | N/A |
| 12/31/2019 | 12 | -3 | N/A | -2 | N/A |
| 9/30/2019 | 11 | -1 | N/A | -1 | N/A |
| 6/30/2019 | 10 | 0 | N/A | -1 | N/A |
| 3/31/2019 | 9 | 0 | N/A | 0 | N/A |
| 12/31/2018 | 9 | 0 | N/A | 1 | N/A |
| 9/30/2018 | 8 | 0 | N/A | 1 | N/A |
| 6/30/2018 | 7 | 0 | N/A | 0 | N/A |
| 3/31/2018 | 7 | 0 | N/A | 0 | N/A |
| 12/31/2017 | 6 | 0 | N/A | 0 | N/A |
| 9/30/2017 | 6 | 0 | N/A | 0 | N/A |
| 6/30/2017 | 6 | 0 | N/A | 1 | N/A |
| 3/31/2017 | 6 | -1 | N/A | 0 | N/A |
| 12/31/2016 | 6 | -1 | N/A | 0 | N/A |
| 9/30/2016 | 4 | -1 | N/A | 0 | N/A |
| 6/30/2016 | 4 | -2 | N/A | -1 | N/A |
| 3/31/2016 | 3 | -1 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -2 | N/A | -1 | N/A |
| 9/30/2015 | 3 | -1 | N/A | -1 | N/A |
| 6/30/2015 | 3 | -2 | N/A | -1 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SMTIDas prognostizierte Gewinnwachstum (105.5% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: SMTIDie Erträge des Unternehmens (105.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.8% pro Jahr).
Hohe Wachstumserträge: SMTIEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: SMTIDie Einnahmen des Unternehmens (11.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: SMTIDie Einnahmen des Unternehmens (11.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SMTI in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 10:59 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Sanara MedTech Inc. wird von 2 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |